# A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

> **NCT03284931** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 45 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SAGE-217 high dose
- **DRUG:** Placebo
- **DRUG:** SAGE-217 low dose

## Key facts

- **NCT ID:** NCT03284931
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-14
- **Primary completion:** 2017-12-04
- **Final completion:** 2017-12-18
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284931, "A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03284931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*